Post hoc analysis of a phase 3 trial of tenecteplase vs alteplase in 1,577 ischaemic stroke patients: 13.9% had serious adverse events within 24 h, with no difference by thrombolytic; SAEs were linked to worse 90-day mRS (OR 3.93).
Secondary analysisn = 1,577 patients
Appoo et al. Predictors and Consequences of Serious Adverse Events in Patients Treated With Thrombolysis: A Prespecified Secondary Analysis of the AcT Trial